Get the Stockscreener App
5.22
3.69%
-0.20
Pre-market:
4.41
-0.81
-15.52%
Cns Pharmaceuticals Inc stock is traded at $5.22, with a volume of 943.33K.
It is down -3.69% in the last 24 hours and up +122.13% over the past month.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
See More
Previous Close:
$5.42
Open:
$4.91
24h Volume:
943.33K
Relative Volume:
0.70
Market Cap:
$7.63M
Revenue:
-
Net Income/Loss:
$-15.85M
P/E Ratio:
-0.2184
EPS:
-23.9055
Net Cash Flow:
$-13.83M
1W Performance:
+9.21%
1M Performance:
+122.13%
6M Performance:
-22.55%
1Y Performance:
-60.45%
1-Day Range:
$4.68
$5.61
1-Week Range:
$4.65
$5.61
52-Week Range:
$1.90
$13.80
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
5.22 | 7.92M | 0 | -15.85M | -13.83M | -23.91 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
[EFFECT] CNS Pharmaceuticals, Inc. SEC Filing - Stock Titan
CNS Pharmaceuticals (NASDAQ: CNSP) registers 9.79M resale shares from May private placement - Stock Titan
CNSP SEC FilingsCNS Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Buying: Faith Charles Acquires Shares of CNS Pharmaceuti - GuruFocus
CNS Pharmaceuticals director Faith L. Charles buys $34,001 in stock By Investing.com - Investing.com Canada
CNS Pharmaceuticals director Faith L. Charles buys $34,001 in stock - Investing.com
CNSP | CNS Pharmaceuticals, Inc. Common Insider Trading - Quiver Quantitative
[Form 4] CNS Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress - Weatherford Democrat
CNS Pharmaceuticals Registers 9.79 Million Shares for Selling Holders - Moomoo
CNS Pharmaceuticals (CNSP) registers 9.79M shares including prefunded warrants - Stock Titan
cns pharmaceuticals inc Earnings dates - RTTNews
NRXP: Advanced CNS drug pipeline, reduced net loss, and expanded clinical footprint in Q1 2026 - TradingView
Stonepine (CNSP) reports 159,790 shares; 9.9% position disclosed - Stock Titan
Maxim Group Maintains CNS Pharmaceuticals(CNSP.US) With Buy Rating, Maintains Target Price $10 - Moomoo
CNSP Poised for Growth Through Strategic Initiatives - GuruFocus
CNS Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CNSP's Financial Outlook After Recent Fundraising - GuruFocus
CNS Pharmaceuticals, Inc. Q1 2026 Financials and Corporate Strategy Update – 10-Q Report Highlights - Minichart
CNS Pharmaceuticals : CNSP - 24/7 Wall St.
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress - ACCESS Newswire
Biotech CNS Pharmaceuticals secures $22.5M to buy neurology, oncology drugs - Stock Titan
CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CNS Pharmaceuticals (CNSP) widens Q1 loss but secures $22.5M private placement - Stock Titan
ACADIA Pharmaceuticals stock (US0042251084): Biotech decline amid CNS focus - AD HOC NEWS
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6 - 24/7 Wall St.
TradingKey - TradingKey
CNS Pharmaceuticals Inc expected to post a loss of $5.37 a shareEarnings Preview - TradingView
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Why did CNSP stock surge 330% today? - MSN
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing - ACCESS Newswire
ACADIA Pharmaceuticals stock (US0042251084): Focus on CNS drug pipeline and commercial execution - AD HOC NEWS
Is CNS Pharma (CNSP) stock hiding in plain sight? (Trend Strengthens) 2026-05-08Trending Volume Leaders - newser.com
CNS Pharmaceuticals Company Profile & Introduction - Moomoo
What's Going On With CNS Pharmaceuticals Stock On Wednesday? - Sahm
Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot - Sahm
Nano-cap CNS Pharmaceuticals stock explodes as capital raise fuels pivot - MSN
CNS Pharma sees 250% spike from oversubscribed private placement - Mugglehead Investment Magazine
CNS Pharmaceuticals (CNSP) Stock Skyrockets 215% on $22.5M Funding Round - MEXC Exchange
Why CNS Pharmaceuticals (CNSP) Stock Is Up 215% Today - MEXC
Why Did CNSP Stock Surge 330% Today? - Stocktwits
CNSP Secures $22.5 Million in Private Placement Financing - GuruFocus
CNS Pharmaceuticals (CNSP) Stock Skyrockets 215% on $22.5M Fundraise - MEXC
CNS Pharmaceuticals Raises $22.5 Million in Private Placement to Fuel Asset Acquisition - MEXC
CNS Pharmaceuticals (NASDAQ: CNSP) Secures $22.5M Private Placement Financing - The Globe and Mail
Gold Falls Over 2%; US Factory Orders Rise In March - Benzinga
CNS Pharmaceuticals Announces Private Placement Agreement and Pre-Funded Warrants Offering – Details and Legal Terms - Minichart
Why is CNS Pharmaceuticals stock up 250% today? By Investing.com - Investing.com Nigeria
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):